Business Wire

C3.ai Announces COVID-19 Grand Challenge Winners

8.12.2020 17:00:00 EET | Business Wire | Press release

Share

C3.ai, a leading enterprise artificial intelligence (AI) software provider for accelerating digital transformation, today announced the winners of the C3.ai™ COVID-19 Grand Challenge. Launched on Sept. 15, the global competition encouraged developers, data scientists, students, and creative minds to build world-class data science techniques and strategies that accelerate novel COVID-19 research and drive smart and safe decision-making. The C3.ai COVID-19 Grand Challenge represents an opportunity to inform decision makers at the local, state, and federal levels and transform the way the world confronts this pandemic.

After a rigorous review process, the judging panel selected seven research projects for recognition. Judges assessed how well the entries leveraged data science techniques to derive insights that were not apparent before. The judges selected submissions that were most likely to unlock significant public health and economic benefits.

A total of $200,000 in cash prizes will be awarded to these research teams. Each has developed meaningful data-driven insights that will help the global community understand and mitigate not only the spread of COVID-19, but also prepare the world to fight future pandemics, improve the medical community’s ability to respond, and help policymakers navigate decisions about COVID-19.

C3.ai Grand Challenge Award Winners:

Grand Prize - $100,000

  • Combined Diagnostics - Modeling Population Heterogeneity and Personalized COVID Diagnostics. Predicts an individual’s infectious and susceptibility status and probability of having COVID-19. The team applied the Bayesian Stochastic Expectation-Maximization method to demographics, individual health characteristics, and behavioral and geographical data to provide personalized estimates for each individual’s infectious and susceptibility statuses. (Freddy Bunbury - Carnegie Institution for Science, Nina Miolane - University of California, Santa Barbara, and Claire Donnat - University of Chicago)

“Any return to normality relies on accurately determining who might have COVID-19. Demographics, individual health characteristics, and behavioral and geographical data considerably alter one’s risk of catching, suffering from, and spreading the virus,” said Freddy Bunbury, post-doctoral researcher at the Carnegie Institution for Science. “Knowing this, we developed a machine learning model that is reactive, granular, and even personalized to help individuals, and – by extension – society, compute with greater accuracy the probability of having COVID-19. By intelligently combining these disparate data sources, we aim to more robustly capture people’s individual likelihood of having and spreading the disease, reduce false test results, and inform disease transmission models.”

“This project has huge potential to make an immediate impact on the pandemic with its approach to generating meaningful results from COVID testing,” said Thomas M. Siebel, CEO of C3.ai. “This is an unprecedented opportunity to apply informed decision-making based on data to enable daily life and business operations to continue, while effectively managing health risks.”

Second-Place Awards - $25,000 each

  • DeepOutbreak: Framework for Forecasting Dynamics of COVID-19 and Co-Evolving Diseases. Models the progression of COVID-19 and symptomatically similar co-evolving influenza-like illnesses, as well as hospitalization and mortality rates. Designed to optimize healthcare deployment, which is especially important with hospitalizations resurging and healthcare workers increasingly becoming ill. (Alexander Rodriguez, Nikhil Muralidhar, Bijaya Adhikari, Naren Ramakrishnan, and B. Aditya Prakash - U.S.)
  • Assessing Conservation Level of Therapeutic and Vaccine Targets of COVID-19. Predicts the effectiveness of vaccines and therapeutics by genome sequences and prioritizes relevant treatments to inform drug and vaccine development. (Yuanfang Guan and Manqi Zhou - U.S.)

Third-Place Awards - $12,500 each

  • Analysis of COVID-19 Policies’ Impact on the Population and the Economy . Calculates the impact of government policies on COVID-19 infection rates, stock prices, and a population’s mobility to inform governments about how policies affect people and the economy. (Niti Wattanasirichaigoon, Napat Ratanakul, and Apiwat Jaroonpol - U.S., Singapore, and Japan)
  • COVIDProf: An Intelligent Q&A Chatbot Tuned to Deliver Scientific Research and Data Related to COVID-19 in Natural Language. Makes finding and understanding relevant COVID-19 scientific research and data easier for the average person through an intelligent Q&A chatbot. (Varsha Rao and Joy Yeh - Singapore and Japan)
  • Structural Modeling of COVID Spread in Relation to Human Mobility . Models causal relationships between human mobility indicators (trips, distance traveled, staying at home, and social distancing) and COVID-19 spread to inform how policymakers should take action. (Rezwana Rafiq, Tanjeeb Ahmed, and Md Yusuf Sarwar Uddin - U.S.)
  • The Center on Stochastic Modeling, Optimization, and Statistics (COSMOS) COVID -19 Linear Programming. Online tool for reopening communities that enables decision makers to study hypothetical scenarios to inform planning and protect high-risk individuals. (Victoria Chen, Yuan Zhou, Nilabh Ohol, Alireza Fallahi, and Amith Viswanatha - U.S.)

Award Criteria

The projects were reviewed on the basis of their scientific merit, the use of AI, machine learning, and/or other data science techniques in the project, and the incorporation of at least two data sources from the C3 AI® COVID-19 Data Lake.

The evaluation process also considered the extent to which the derived data science insights, if implemented at scale, will result in significant public health and economic benefit.

To learn more about the C3.ai COVID-19 Grand Challenge, please visit https://c3.ai/c3-ai-covid-19-grand-challenge/.

About C3.ai

C3.ai is a leading AI software provider for accelerating digital transformation. C3.ai delivers the C3 AI Suite for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications in addition to an increasingly broad portfolio of turnkey AI applications. The core of the C3.ai offering is a proprietary, model-driven AI architecture that dramatically enhances data science and application development.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lisa Kennedy
415-914-8336
pr@c3.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye